Presentations of Hypertrophic Cardiomyopathy on Myocardial Perfusion Imaging

Study Overview
=================
Brief Summary
-----------------
Chest pain and myocardial ischemia are prevailing features in patients with hypertrophic cardiomyopathy (HCM). Recently introduced single-photon emission computed tomography (SPECT) cameras with solid-state cadmium-zinc-telluride (CZT) detectors have been shown to decrease imaging time and improved the imaging quality of gated myocardial perfusion imaging (MPI). The investigators also correlate the MPI parameters with echocardiographic parameters. This study is to examine the spatial distribution of stress perfusion abnormalities and tissue injury in patients with HCM using a CZT SPECT camera.

Detailed Description
-----------------
The investigators will retrospectively evaluate myocardial perfusion patterns and cardiac function with Thallium (Tl)-201 gated dipyridamole MPI in patients with clinical diagnosis of HCM and patent coronary angiography between January 2013 and October 2016. The inclusion criteria included a spade-like configuration on left ventriculogram, or echocardiographic findings suggestive of HCM. The participants will be then divided into the following three groups: apical, concentric and septal forms. Regional perfusion would be analyzed using a 17-segment model from 0-4 degree (0=normal, to 4=absent perfusion); and summed stress score (SSS), summed rest score (SRS) and summed difference score (SDS) were calculated. Gated SPECT would be processed by quantitative gated SPECT (QGS) software (Cedars-Sinai Medical Center, Los Angeles, CA, USA) and ejection fraction phase analysis. Diastolic parameters would be also acquired by Doppler echocardiography, and correlated with MPI parameters.

Official Title
-----------------
Presentations of Hypertrophic Cardiomyopathy on Myocardial Perfusion Imaging

Conditions
-----------------
Hypertrophic Cardiomyopathy, Myocardial Perfusion Imaging

Intervention / Treatment
-----------------
* Diagnostic Test: myocardial perfusion imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of HCM and patent coronary angiography between January 2013 and October 2016. Exclusion Criteria: patient with prior myocardial ischemia, conduction abnormality, valvular disease or other cardiomyopathy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: myocardial perfusion imaging|dipyridamole-stressed MPI scan using thallium-201|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| MPI results | including perfusion abnormalities, and ejection fraction phase analysis results | January 2013 and October 2016. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CZT scanner, myocardial perfusion imaging, Hypertrophic Cardiomyopathy